{
  "id": 20653914,
  "title": "Phathom: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/11/18/phathom-3-key-takeaways-for-long-term-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T20:45:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/11/18/phathom-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Phathom reported $84.7 million in net revenues for Q3 2026, marking a 71% year-over-year growth. The company is expanding coverage for VOQUEZNA, its GERD treatment, through initiatives such as educating physicians on prior authorization and offering $0 copay through partner pharmacy BlinkRx. Phathom's second consecutive quarter of operating profitability and positive cash flow demonstrates sustainable growth, with revenue expected to outpace operating expenses, satisfying debt covenants and positioning the company well for the fourth quarter and beyond.",
  "summary": "Back-to-back quarters of operating profit show the company is converting revenue growth into cash, a milestone that matters for debt covenants and financial sustainability.",
  "key_points": [
    "Phathom reported $84.7 million in net revenues for Q3 2026, a 71% year-over-year growth.",
    "The company is expanding VOQUEZNA coverage through physician education and $0 copay via BlinkRx.",
    "Phathom achieved operating profitability and positive cash flow for two consecutive quarters."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}